SGI-1776 free base
1025065-69-3
99%
2026-06-30
Coenzymes,Inhibito,Enzymes,Zymogens,Substrates,Native Microorganism Creatine Amidinohydrolase
-
Product Description
-
Seller Information
-
Description
ProductName SGI-1776 free base Cat No CEI-0197 Description SGI-1776 free base can inhibit Pim1, Pim2, and Pim3 with IC50 of 7 nM, 363 nM and 9 nM. CAS No 1025065-69-3 Molecular Weight 405.42 Purity >99% Storage 2 years at -20centigrade Powder Targets Pim1, Pim2, Pim3 Molecular Formula C20H22F3N5O Chemical Name N-((1-methylpiperidin-4-yl)methyl)-3-(3-(trifluoromethoxy)phenyl)imidazo[1,2-b]pyridazin-6-amine Solubility DMSO 81 mg/mL Water In vitro SGI-1776 can potently inhibit Pim-1, Pim-2 and Pim-3 with IC50 of 7 nM, 363 nM and 69 nM. SGI-1776 also can inhibit Flt-3 and haspin with IC50 of 44 nM and 34 nM. SGI-1776, as an inhibitor of PIM kinase, shows inhibition to B-cell chronic lymphocytic leukemia (CLL). Pim kinases are over-expressed in B-cell chronic lymphocytic leukemia and inhibition of Pim kinases can affect the survival of B- cell. Besides inhibition to Pim kinases, the level of Mcl-1 protein can be markedly reduced by SGI-1776. Besides inhibition to kinases, SGI-1776 also shows inhibition to RNA synthesis. SGI-1776 can decrease in total RNA synthesis to approximately 50% of control at 10 umol/L. In vivo In AML cell lines (1) SGI-1776 can decrease phosphorylation of c-Myc and 4E-BP1. c-Myc(Ser62) phosphorylation was decreased by 50% relative to control at 0.1uM SGI-1776, which was further reduced by 80% with 1 uM. In MOLM-13 and OCI-AML-3 cell lines, and there was a signi?cant reduction in c-Myc phosphorylation after treatment with SGI-1776. Phosphorylation of translation regulator 4E-BP1 (Thr37/Thr46) was also decreased at 0.1uM SGI-1776 treatment in MV-4-11, MOLM-13 and OCI-AML-3. (2) SGI-1776 can induce apoptosis in AML cell lines. There was a dose-dependent increase in apoptotic cells after treatment with SGI-1776, and there was 25% increase in apoptosis with 10 uM SGI-1776. (3) The inhibition to FLT3-ITD by SGI-1776 is as potent as the inhibition to FLT3-ITD by AC220 in AML cell lines. category Inhibitors(c1514) cas_num 1025065-69-3 Basic Info-
Product Name:
SGI-1776
Other Name:SGI-1776;SGI-1776 free base;N-[(1-Methyl-4-piperidinyl)methyl]-3-[3-(trifluoromethoxy)phenyl]-imidazo[1,2-b]pyridazin-6-amine;N-((1-methylpiperidin-4-yl)methyl)-3-(3-(trifluoromethoxy)phenyl)imidazo[1,2-b]pyridazin-6-amine;N-[(1-Methyl-4-piperidinyl)methyl]-3-[3-(trifluoromethoxy)phenyl]-imidazo[1,2-b]pyridazin-6-amineSGI-1776;SGI-1776, >=98%;SGI-1776 free baseN-[(1-Methyl-4-piperidinyl)methyl]-3-[3-(trifluoromethoxy)phenyl]-imidazo[1,2-b]pyridazin-6-amine;N-[(1-Methyl-4-piperidinyl)methyl]-3-[3-(trifluoromethoxy)phenyl]-imidazo[1,2-b]pyridazin-6-am
CAS No.:1025065-69-3
Molecular Formula:C20H22F3N5O
InChIKeys:MHXGEROHKGDZGO-UHFFFAOYSA-N
Molecular Weight:405.4167896
Exact Mass:405.177643
Categories:
Characteristics-
PSA:
54.7
XLogP3:4.3
Density:1.37
Refractive Index:1.613
Hazard IdentificationClassification of the substance or mixture
no data available
GHS label elements, including precautionary statements
Pictogram(s) no data available Signal word no data available
Hazard statement(s) no data available
Precautionary statement(s) Prevention no data available
Response no data available
Storage no data available
Disposal no data available
Other hazards which do not result in classification
no data available
Handling and StoragePrecautions for safe handling
Handling in a well ventilated place. Wear suitable protective clothing. Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Use non-sparking tools. Prevent fire caused by electrostatic discharge steam.
Conditions for safe storage, including any incompatibilities
Store the container tightly closed in a dry, cool and well-ventilated place. Store apart from foodstuff containers or incompatible materials.
-
-
Seller Information
-
Business Type:
Manufactory
-
Main Products:
Coenzymes,Inhibito,Enzymes,Zymogens,Substrates,Native Microorganism Creatine Amidinohydrolase
-
Location:
Shirley, New York 11967, USA
-
Payment Terms:
TT against copy of documents,D/P
-
Average lead Time:
15
-
Total Annual Revenue:
$1 million-$2.5 million
-
Year of Establishment:
2004
-
-
Country Product Purchase Quantity Date Posted Post an enquiry for this product